(Q46318029)

English

A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18853421%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18853421%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

systemic therapy

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18853421%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Tzy Jyun Yao

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18853421%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Pierre Chan

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18853421%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Kelvin Ng

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18853421%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Sheung Tat Fan

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18853421%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Ronnie T P Poon

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18853421%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

0 references

publication date

1 November 2008

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18853421%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18853421%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

113

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18853421%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18853421%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

2742-2751

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18853421%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

A method of comparing the areas under receiver operating characteristic curves derived from the same cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23878

21 January 2018

Estimating the world cancer burden: Globocan 2000.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23878

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23878

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23878

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23878

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23878

7 January 2021

based on heuristic

inferred from DOI database lookup

A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23878

7 January 2021

based on heuristic

inferred from DOI database lookup

Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23878

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognosis of hepatocellular carcinoma: the BCLC staging classification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23878

7 January 2021

based on heuristic

inferred from DOI database lookup

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23878

7 January 2021

based on heuristic

inferred from DOI database lookup

Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23878

7 January 2021

based on heuristic

inferred from DOI database lookup

Presentation of multivariate data for clinical use: The Framingham Study risk score functions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23878

7 January 2021

based on heuristic

inferred from DOI database lookup

Time-dependent ROC curves for censored survival data and a diagnostic marker

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23878

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23878

7 January 2021

based on heuristic

inferred from DOI database lookup

Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23878

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23878

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46318029&oldid=1502345985"